# A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

> **NCT07668336** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 170 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT07668336
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2030-03
- **Final completion:** 2030-03
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668336, "A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*